Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.39)
# 880
Out of 4,667 analysts
71
Total ratings
50%
Success rate
3.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $24 → $28 | $16.74 | +67.26% | 4 | Nov 15, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.59 | +56.41% | 2 | Nov 7, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $70 → $65 | $35.40 | +83.62% | 3 | Oct 9, 2024 | |
| BNTC Benitec Biopharma | Initiates: Buy | $17 | $10.66 | +59.47% | 1 | Sep 12, 2024 | |
| RZLT Rezolute | Initiates: Buy | $11 | $5.01 | +119.56% | 1 | Aug 27, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $45 → $50 | $29.99 | +66.72% | 3 | Aug 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $558 | $451.23 | +23.66% | 7 | Aug 2, 2024 | |
| CRSP CRISPR Therapeutics AG | Assumes: Neutral | n/a | $47.26 | - | 1 | Jun 28, 2024 | |
| DTIL Precision BioSciences | Initiates: Buy | $19 | $7.18 | +164.62% | 2 | Apr 30, 2024 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $22 | $5.36 | +310.45% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $20 | $2.99 | +568.90% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $178.10 | -1.74% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $20.01 | +49.93% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $40 | $54.83 | -27.05% | 1 | Nov 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $62.56 | +75.83% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $5.70 | +829.82% | 4 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.05 | +1,314.63% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.51 | +2,041.33% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $46.40 | +7.76% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $248.79 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $130 | $24.49 | +430.83% | 1 | Jan 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.01 | +1,293.03% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $170 | $13.12 | +1,195.73% | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $14.26 | +40.25% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $221 | $110.86 | +99.35% | 4 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $25.64 | +379.72% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $14.55 | +271.13% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $2.71 | +2,114.02% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.62 | - | 3 | Jun 26, 2017 |
Centessa Pharmaceuticals
Nov 15, 2024
Maintains: Buy
Price Target: $24 → $28
Current: $16.74
Upside: +67.26%
Amicus Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.59
Upside: +56.41%
Ionis Pharmaceuticals
Oct 9, 2024
Maintains: Buy
Price Target: $70 → $65
Current: $35.40
Upside: +83.62%
Benitec Biopharma
Sep 12, 2024
Initiates: Buy
Price Target: $17
Current: $10.66
Upside: +59.47%
Rezolute
Aug 27, 2024
Initiates: Buy
Price Target: $11
Current: $5.01
Upside: +119.56%
Dyne Therapeutics
Aug 15, 2024
Maintains: Buy
Price Target: $45 → $50
Current: $29.99
Upside: +66.72%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $451.23
Upside: +23.66%
CRISPR Therapeutics AG
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $47.26
Upside: -
Precision BioSciences
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $7.18
Upside: +164.62%
Voyager Therapeutics
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $5.36
Upside: +310.45%
Mar 5, 2024
Maintains: Buy
Price Target: $24 → $20
Current: $2.99
Upside: +568.90%
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $178.10
Upside: -1.74%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $20.01
Upside: +49.93%
Nov 21, 2023
Assumes: Buy
Price Target: $40
Current: $54.83
Upside: -27.05%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $62.56
Upside: +75.83%
Feb 28, 2023
Reiterates: Buy
Price Target: $53
Current: $5.70
Upside: +829.82%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.05
Upside: +1,314.63%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.51
Upside: +2,041.33%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $46.40
Upside: +7.76%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $248.79
Upside: -
Jan 5, 2022
Initiates: Buy
Price Target: $130
Current: $24.49
Upside: +430.83%
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $2.01
Upside: +1,293.03%
Oct 5, 2021
Initiates: Buy
Price Target: $170
Current: $13.12
Upside: +1,195.73%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $14.26
Upside: +40.25%
Aug 31, 2020
Maintains: Buy
Price Target: $260 → $221
Current: $110.86
Upside: +99.35%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $25.64
Upside: +379.72%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $14.55
Upside: +271.13%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $2.71
Upside: +2,114.02%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $54.62
Upside: -